Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Working Capital Changes: 2012-2024

Historic Other Working Capital Changes for Ultragenyx Pharmaceutical (RARE) over the last 13 years, with Dec 2024 value amounting to -$11.7 million.

  • Ultragenyx Pharmaceutical's Other Working Capital Changes rose 22.12% to -$9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 170.83%. This contributed to the annual value of -$11.7 million for FY2024, which is 23.45% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Other Working Capital Changes stood at -$11.7 million for FY2024, which was up 23.45% from -$15.3 million recorded in FY2023.
  • Ultragenyx Pharmaceutical's 5-year Other Working Capital Changes high stood at $29.5 million for FY2021, and its period low was -$15.3 million during FY2023.
  • For the 3-year period, Ultragenyx Pharmaceutical's Other Working Capital Changes averaged around -$10.3 million, with its median value being -$11.7 million (2024).
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first surged by 1,173.80% in 2021, then crashed by 303.50% in 2023.
  • Ultragenyx Pharmaceutical's Other Working Capital Changes (Yearly) stood at -$2.7 million in 2020, then skyrocketed by 1,173.80% to $29.5 million in 2021, then plummeted by 112.87% to -$3.8 million in 2022, then plummeted by 303.50% to -$15.3 million in 2023, then rose by 23.45% to -$11.7 million in 2024.